comparemela.com

Latest Breaking News On - மூளை அறிவியல் இன்க் - Page 1 : comparemela.com

Disposable EEG Electrode Market Size Worth $921 3 Million By 2028: Grand View Research, Inc

SAN FRANCISCO, June 9, 2021 /PRNewswire/ The global disposable EEG electrode market size is expected to reach USD 921.3 million by 2028, according to a new report by Grand View Research,

Brain Scientific Files Its Annual Report on Form 10-K Announcing 2020 Results

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Brain Scientific Files Its Annual Report on Form 10-K Announcing 2020 Results Brain Scientific Inc.April 19, 2021 GMT NEW YORK, April 19, 2021 (GLOBE NEWSWIRE) via InvestorWire – Brain Scientific Inc. (OTCQB: BRSF) (the “Company” or “Brain Scientific”), a neurology-focused medical device and software company, filed its Annual Report on Form 10-K for the fiscal year ended Dec. 31, 2020, with the U.S. Securities and Exchange Commission (SEC). Brain Scientific is a neurodiagnostic and predictive technology platform company seeking to provide a centralized platform for data acquisition and analysis of EEG data that combines innovative medical device technologies with cloud-based telehealth services.

Ehave Prepares to Launch Ketamine Clinical Trials Using Brain Scientific s Brain Mapping Technology

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Ehave Prepares to Launch Ketamine Clinical Trials Using Brain Scientific’s Brain Mapping Technology EhaveApril 16, 2021 GMT MIAMI, April 16, 2021 (GLOBE NEWSWIRE) Ehave, Inc. (OTC Pink: EHVVF) (the “Company”), a provider of digital therapeutics for the psychedelic and mental health sectors, announced today plans to launch brain mapping ketamine clinical trials using Brain Scientific technology later this year. The clinical trial will establish the statistical correlation between the ketamine treatment and patient improvement from the disorders. The trial, which is designed to enroll 35 patients, is expected to start in the second half of 2021. Ehave is currently completing the necessary preclinical studies necessary to begin enrolling patients in the trial. The average drop out ratio of clinical trials is around 15 % and Ehave will need at least 25-30 patients’ egg data to es

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.